4,5-diarylimidazole derivatives as HDAC inhibitors
AssigneesCharite-Universitatsmedizin Berlin, Universitat Bayreuth
InventorsMichael Höpfner, Bernhard Biersack, Rainer Schobert, Katharina Mahal
Life of this patent
Estimating the term…
Abstract
The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
Claims11
A 4,5-diarylimidazole derivative of formulae (I), (II) or (III):
- or a pharmaceutically acceptable salt thereof,
- wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring;
- and wherein
- R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group;
- R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group;
- M is a metal atom;
- L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I);
- and n is an integer of from 1 to 5.
Dependencies are inferred from the claim text.